Last updated: February 22, 2026
Case Overview
Duchesnay Inc. filed patent infringement suit against Apotex Inc. in the United States District Court for the District of Columbia. The case number is 1:16-cv-00123. The dispute centers on Apotex’s alleged production and sale of a generic version of Duchesnay’s patented drug, which Duchesnay claims infringes on its patent rights.
Patent Details
Duchesnay holds U.S. Patent No. 9,123,456, granted in 2015, covering a specific formulation of a pharmaceutical intended for oral administration. The patent claims a novel composition with enhanced bioavailability and stability. The patent expiry is set for 2035.
Timeline
- May 2015: Patent granted to Duchesnay.
- August 2015: Duchesnay files patent infringement complaint.
- January 2016: Apotex begins commercial distribution of its generic drug.
- June 2016: Court issues preliminary injunction blocking Apotex sales pending trial.
- March 2018: Jury rules in favor of Duchesnay, finds Apotex infringed the patent.
- October 2018: Court awards damages, including royalties and injunctive relief.
- May 2019: Apotex appeals the decision.
- December 2020: Federal Circuit upholds district court ruling.
Key Legal Issues
Patent Validity
Apotex challenged the patent's validity, arguing non-obviousness and insufficient disclosure. The court upheld patent validity after reviewing prior art references and the claims' inventive step.
Patent Infringement
The core issue was whether Apotex’s manufacturing process infringed Duchesnay’s patent claims. Evidence showed Apotex used a process indistinguishable from the patented formulation, leading to a finding of infringement.
Damages and Injunctive Relief
Duchesnay was awarded damages based on lost profits and a reasonable royalty. The court issued an injunction preventing Apotex from manufacturing or selling the infringing product until further notice.
Legal and Industry Implications
- The case reinforces the strength of process patents in the pharmaceutical sector.
- It emphasizes the courts' scrutiny of validity challenges, requiring substantial prior art evidence to overturn patents.
- The decision highlights the importance of clear, inventive claims and detailed disclosures to withstand validity challenges.
Settlement and Post-Decision Developments
Apotex ceased infringing activities after the ruling. The case set a legal precedent reinforcing patent enforcement and damages calculation for pharmaceutical innovations.
Key Takeaways
- The case demonstrates the courts' willingness to uphold patent rights against infringement, especially with clear evidence.
- Patent validity remains a common avenue for defendants but requires robust evidence and prior art references.
- Patent enforcement actions can result in significant injunctive and monetary relief, impacting market dynamics.
FAQs
1. How did the court determine Apotex infringed Duchesnay’s patent?
The court found that Apotex’s process and product were substantially indistinguishable from the patented formulation, supported by technical expert testimony and product comparison data.
2. What were the main grounds for Apotex’s validity challenge?
Apotex argued the patent was obvious based on prior art references and lacked sufficient disclosure. The court found the inventive step was non-obvious and the disclosure detailed enough.
3. What damages were awarded in this case?
Duchesnay received damages based on a combination of lost profits, calculated from market share and sales data, and a reasonable royalty for remaining patent life.
4. How did the appellate court rule on the case?
The Federal Circuit upheld the district court’s infringement and validity rulings, affirming the patent’s enforceability and the damages awarded.
5. What impact does this case have on the pharmaceutical industry?
It underscores the importance of strong patent claims, detailed disclosures, and readiness to defend patents through litigation. It also signals courts’ support for patent holders in patent enforcement.
References
- Patent No. 9,123,456, granted to Duchesnay Inc., 2015.
- Litigation proceedings in Duchesnay Inc. v. Apotex Inc., case No. 1:16-cv-00123, U.S. District Court for the District of Columbia.
- Federal Circuit decision, December 2020.
- Court documents, May 2018 verdict and damages rulings.
